the aid library

LIST OPTIONS

Filter

9273

Sport and Asthma

Green, R.; Nagel, F. National Asthma Education Programme (2012) CC2

People with asthma should be encouraged to take part in any sport they choose. If someone with asthma is having difficulty with sport, it means their asthma may not be under control. You will need to see your doctor to review your controller treatment... more

Asthma medicines and how they work

National Asthma Education Programme (2012) CC2

Asthma is a chronic lung disease, which means it cannot be cured. But with the right treatment asthma can be kept under control so that those affected area be to live completely normal lives enjoyingfull involvement in sport ... all other activities. more

Sustainable management of radiotherapy facilities and equipment

World Health Organization (WHO) World Health Organization (WHO) (2023) C_WHO

The document, "Sustainable Management of Radiotherapy Facilities and Equipment," by WHO and IAEA, provides guidelines for managing radiotherapy equipment ... facilities to ensure effective and safe cancer treatment. It covers essential aspects like preventive and corrective maintenance, funding, infrastructure, and staffing requirements for sustainable operation. The document aims to support radiotherapy departments, especially in low-resource settings, by outlining strategies for equipment procurement, maintenance, and replacement, emphasizing safety, quality assurance, and optimal patient care. more

Barriers and determinants of asthma control in children and adolescents in Africa: a systematic review

Mphahlele, R.E.; Kitchin, O.; Masekela, R. BMJ Open (2021) CC

The article "Barriers and determinants of asthma control in children and adolescents in Africa: a systematic review" analyzes factors contributing to poor asthma control in African youth. Based on s... more

Drug Prevention

Federal Centre for Health Education (BZgA) Federal Centre for Health Education (BZgA) (2024) CC

The Federal Centre for Health Education (BZgA) emphasizes the critical role of drug prevention in enhancing public health in Germany. Annually, the country faces significant premature mortality due to substance use: at least 110,000 deaths from smok... more

External Link

Chagas Disease Treatment Market Huge Growth in Future Scope 2023-2030

Coherent Market Insights Digital Journal (2023) C1

Coherent Market Insights has announced the addition of Chagas Disease Treatment Market 2023 Forecast Analysis by Types, Applications, Size, Share, Key Players, and Regions. a new research report to ... more

Download (290)

View PDF (386)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Types of Insulin

Center for Disease Control and Prevention (CDC) (2023) CC2

The CDC webpage "Types of Insulin" provides an overview of the various insulin types used in diabetes management, categorized by their onset, peak time, and duration of action. It explains terms like onset (how quickly insulin lowers blood sugar), p... more

Asthma: Using a metered dose inhaler (inhaler in mouth)

Center for Disease Control and Prevention CDC (2010) CC2

Manual: Know How to Use Your Asthma Inhaler. Using a metered dose inhaler (inhaler in mouth).

Cystic Fibrosis - What Is Cystic Fibrosis

National Heart, Lung, and Blood Institute (NHLBI) U.S. Department of Health and Human Services (2024) CC2

The "Cystic Fibrosis Fact Sheet" by the National Heart, Lung, and Blood Institute provides an overview of cystic fibrosis (CF), a chronic and often fatal genetic disorder affecting the respiratory <... digestive systems. The document outlines the causes, genetic inheritance patterns, and symptoms of CF, which include thick mucus buildup, respiratory issues, and digestive problems. It also discusses diagnostic methods, such as the sweat test and genetic testing, and highlights current treatment approaches focused on symptom management, including chest therapy, medications, and potential gene therapy. The fact sheet emphasizes patient and family education to improve quality of life and support coping strategies. more

Download (2232)

View PDF (3362)

For Proper Disposal Hospital Waste

Jorge Emmanuel and Ruth Stringer Health Care Without Harm (2007)

A Global Inventory of Alternative Medical Waste Treatment Technologies

Malawi - HIV Country Profile 2024

World Health Organization WHO (2024) C_WHO

Demographic and socioeconomic data Progress towards HIV testing and treatment cascade targets by 2025 (2023) Health sector cascade (2023) Estimat... more

Access the KAP Knowledge Repository

World Health Organization WHO (2024) C_WHO

Readily access selected guidelines, reports and other knowledge resources to enhance evidence-informed, multisectoral, and multistakeholder initiatives in NCD ... and control – curated by WHO's Global NCD Platform and supported by GCM Participants. more

Toolkit for developing a multisectoral action plan for noncommunicable diseases: overview

World Health Organization (WHO) World Health Organization (WHO) (2022) C_WHO

This toolkit is a "how to" guide for developing, implementing and evaluating a multisectoral action plan for prevention and control of NCDs. It is ... more

Toolkit for developing a multisectoral action plan for noncommunicable diseases: overview 2022

World Health Organization (WHO) World Health Organization (WHO) (2022) C_WHO

This toolkit is a "how to" guide for developing, implementing and evaluating a multisectoral action plan for prevention and control of NCDs. It is ... more

¿Qué es la tuberculosis? - Enfermedad y síntomas

Draw my life en espanol Youtube (2024) C2

The video titled "¿QUÉ ES LA TUBERCULOSIS? - ENFERMEDAD y SÍNTOMAS" (What is Tuberculosis? - Disease and Symptoms) provides an overview of tuberculosis (TB), detailing its causes, transmission methods, symptoms, ... treatment options. It emphasizes the importance of early detection and treatment to prevent the spread of TB and highlights the global impact of the disease. The video also discusses preventive measures and the significance of public awareness in combating tuberculosis. more

Keeping Asthma under control

National Asthma Education Programme (2012) CC2

Asthma usually causes symptoms over a long period and cannot be cured. But asthma can be kept under control so that those affected are able to live enjoying full involvement in sport and all other a... more

Download (656)

View PDF (1670)

Delivering quality health services: A global imperative for universal health coverage

Kieny, Marie-Paule; Evans, Timothy Grant; Scarpetta, Stefano; Kelley, Edward T.; Klazinga, Niek; Forde, Ian; Veillard, Jeremy Henri Maurice; Leatherman, Sheila; Syed, Shamsuzzoha; Kim, Sun Mean; Nejad, Sepideh Bagheri; Donaldson, Liam World Health Organization (WHO), Organisation for Economic Co-operation and Development (OECD), and The World Bank (2018) C_WHO

Poor quality health services are holding back progress on improving health in countries at all income levels.
Today, inaccurate diagnosis, medication errors, inappropriate or unnecessary treatment, inadequate or unsafe clinical facilities or pr... more

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular disease in patients with diabetes of the Eur

Marx, N.; Federici, M.; Schütt, K. et al. European Heart Journal (2023) CC

Patients with diabetes are at increased risk of developing cardiovascular disease (CVD) with its manifestations of coronary artery disease (CAD), heart failure (HF), atrial fibrillation (AF), and stroke, as well as aortic ... peripheral artery diseases. In addition, diabetes is a major risk factor for developing chronic kidney disease (CKD), which in itself is associated with developing CVD. The combination of diabetes with these cardio-renal comorbidities enhances the risk not only for cardiovascular (CV) events but also for CV and all-cause mortality. The current European Society of Cardiology (ESC) Guidelines on the management of cardiovascular disease in patients with diabetes are designed to guide prevention and management of the manifestations of CVD in patients with diabetes based on data published until end of January 2023. Over the last decade, the results of various large cardiovascular outcome trials (CVOTs) in patients with diabetes at high CV risk with novel glucose- lowering agents, such as sodium–glucose co-transporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists (RAs), but also novel non-steroidal mineralocorticoid receptor antagonists (MRAs), such as finerenone have substantially expanded available therapeutic op- tions, leading to numerous evidence-based recommendations for the management of this patient population. more

Surveillance of NCDs

World Health Organization WHO; Eastern Mediterranean Region World Health Organization (WHO) (2024) C_WHO

The WHO Eastern Mediterranean Region's Noncommunicable Diseases (NCD) Data and Statistics page offers comprehensive information on NCD surveillance, including mortality rates, morbidity, and risk fa... more